drugset
drugset / Trial / NCT03925324

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

NCT03925324 ↗

Phase 2 Terminated 4 enrolled Medstar Health Research Institute
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.

Timeline

Start
2019-05-03
Primary completion
2021-08-16
Completion
2021-08-16

Outcome

Outcome not reported

Stopped (Business): “Lack of funding/Covid-19”

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Mesenchymal Bone Marrow Cells Cell therapy 1.5e+06 cells/kg Intravenous

Indications

intrinsic cardiomyopathy myocardial ischemia